Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Japan’s Nikkei Drops as Markets Await Key U.S. Inflation Data 
Waymo Issues Recall After Reports of Self-Driving Cars Illegally Passing School Buses in Texas 
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains 
Spain’s Industrial Output Records Steady Growth in October Amid Revised September Figures 
Trump Meets Mexico and Canada Leaders After 2026 World Cup Draw Amid USMCA Tensions 
Spirit Airlines Reverses Pilot Furlough Plans Amid Updated Staffing Outlook 
Austria’s AA Credit Rating Affirmed as Fitch Highlights Stable Outlook 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Asian Currencies Steady as Rupee Hits Record Low Amid Fed Rate Cut Bets 
European Oil & Gas Stocks Face 2026 With Cautious Outlook Amid Valuation Pressure 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
U.S. Stocks End Week Higher as Markets Anticipate Fed Rate Cut 
Lotte Biologics has inked a memorandum of understanding (MOU) with Roche Diagnostics to bolster its Contract Development and Manufacturing Organization (CDMO) capabilities. This collaboration signifies major diagnostics, hardware, and automation advancements for Lotte's upcoming Korean production plants.
On Wednesday, Aug. 9, Lotte Biologics said it will work with Roche Diagnostics to improve the productivity and quality of its productions. The company said they would also team up to establish hardware and automation systems for Lotte's upcoming production plants in Korea, as per Korea Joongang Daily.
The MOU was signed at Roche Diagnostics CustomBiotech Center in Penzberg, Germany. Lotte Biologics' chief executive officer, Richard Lee; Roche Diagnostics CustomBiotech's vice president, Rainer Mueller; and Roche Diagnostics Korea's general manager, Kit Tang, were all present at the signing ceremony.
With the deal in place, Lotte Biologics aims to amplify its credibility with future global clients. The agreement will also serve as the forefront to underpin and shore up Roche Diagnostics' supply network in the Asian market. This will also give better treatment access to patients around the world.
"Through this MOU, we plan to enhance the production process capabilities of our Korean Mega Plant in collaboration with Roche Diagnostics," Lotte Biologics chief Richard Lee said in a press release. "Through synergy with Roche Diagnostics, an industry leader in the in vitro diagnostic field, LOTTE hopes to improve the efficiency of its operations at the forthcoming Korean Mega Plant, simultaneously augmenting the quality of our manufacturing and fulfilling customer needs."
Finally, Business Korea reported that Lotte Biologics and Roche Diagnostics will cooperate on various business fronts, including installing automation systems at the former's Mega Plants that will be built in Korea. The latter will also provide technical consulting and equipment support for the facilities.
Photo by: Lotte Biologics Newsroom
